ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024

by Oryzon Genomics

2 years ago
ORYZON, Borderline Personality Disorder (BPD)

Oryzon Genomics today announced that it will host a virtual KOL event to review and discuss the topline results from the Phase IIb PORTICO study evaluating vafidemstat in Borderline Personality Disord...

ORYZON Announces Topline Results from Phase IIb PORTICO study of vafidemstat in Borderline Personality Disorder (BPD)

by Oryzon Genomics

2 years ago
vafidemstat, Borderline Personality Disorder (BPD), Oryzon Genomics

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with a strong unmet medical need, today announced topline results from the Pha...

ORYZON to provide corporate progress updates at several events in January

by Oryzon Genomics

2 years ago
Oryzon Genomics S.A.

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that its management will give ...

ORYZON entre las 1000 empresas europeas con mayor inversión en I+D

by Oryzon Genomics

2 years ago
Oryzon Genomics S.A.

Oryzon Genomics S.A. se complace en compartir que, de acuerdo al ranking publicado por la Unión Europea, se encuentra entre las 1000 empresas europeas con mayor inversión en I+D, en concreto en la p...

ORYZON awarded with a grant for ORY-4001 from the ALS Association in the U.S

by Oryzon Genomics

3 years ago
ORY-4001, amyotrophic lateral sclerosis (ALS), HDAC6, ALS Association, Oryzon

The Association has awarded Oryzon a 498,690 USD grant through its Lawrence and Isabel Barnett Drug Development Program to support the regulatory preclinical development of ORY-4001, a highly selectiv...

ORYZON announces a New Financing through a Convertible Bond Program for a total amount of up to €45 million

by Oryzon Genomics

3 years ago
Nice & Green, SA, vafidemstat, Oryzon Genomics

Funding provided by Nice & Green SA, a Swiss private investor, of €8 million in two tranches of €4 million each, plus optional additional tranches of up to €5 million each to be executed in the ...

ORYZON announces Last Patient Last Visit in its Phase IIb PORTICO study for Borderline Personality Disorder (BPD)

by Oryzon Genomics

3 years ago
vafidemstat, ORYZON, Borderline Personality Disorder (BPD)

Oryzon Genomics, S.A. today announced Last Patient Last Visit in its ongoing Phase IIb PORTICO trial, investigating vafidemstat’s efficacy in Borderline Personality Disorder (BPD). Multiple primary ...

ORYZON to provide corporate progress updates at several events in November

by Oryzon Genomics

3 years ago
BIO-Europe 2023, LSX Investival Showcase 2023, Jefferies London Healthcare Conference 2023, Oryzon Genomics

Oryzon reports financial results and corporate updates for quarter ended September 30, 2023

by Oryzon Genomics

3 years ago
Oryzon Genomics

Research and development (R&D) expenses were $3.8 and $12.2 million for the quarter and nine months ended September 30, 2023, respectively, compared to $4.3 and $11.9 million for the quarter and nine ...

ORYZON presents blinded aggregate safety data from vafidemstat’s ongoing Phase IIb PORTICO trial in Borderline Personality Disorder

by Oryzon Genomics

3 years ago
borderline personality disorder (BPD), Phase IIb PORTICO, vafidemstat

ORYZON receives two grants to further explore the role of epigenetic targets in the treatment of neuronal pathologies

by Oryzon Genomics

3 years ago
DICTIONIS Project, MODERN Project

Two collaborative projects with Public Research Centers with a global budget of 2.3 million euros focused on the discovery and validation of new biomarkers and epigenetic targets in the treatment of n...